Tech Company Financing Transactions
Carbon Biosciences Funding Round
Carbon Biosciences, operating out of Lexington, secured $38 million from Agent Capital, Astellas Venture Capital and Camford Capital.
Transaction Overview
Company Name
Announced On
6/21/2022
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series A
Investors
Proceeds Purpose
The company plans to use the Series A funding to advance the development of Carbon's programs for genetic diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
131 Hartwell Ave.
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joel Schneider
Chief Financial Officer
Jason Walsh
Chief Scientific Officer
Robert Kotin
Vice President
Sebastian Aguirre
Vice President
Jeff Moffit
VP - Manufacturing
Josh Merritt
VP - Operations
Lucy Liu
Browse more venture capital transactions:
Prev: 6/21/2022: Stashfin venture capital transaction
Next: 6/21/2022: Psyomics venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs